01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
As health organizations and governments around the world work to contain the coronavirus (COVID-19),...
Read More >
In December 2020, the United States Department of Transportation (DOT) amended the small business si...
Read More >
The fight over the scope of the “ABC test” for determining the status of workers under California ...
Read More >
Congress is poised to overturn two recent judicial interpretations of the whistleblower protections ...
Read More >
On September 5, 2019, the Washington Supreme Court held that non-agricultural employees do not have ...
Read More >
Former PG&E lawyer named new regional EPA chief in California - Los Angeles Times – February 11 -...
Read More >